In brief, all CXCR3 therapies aim to induce the secretion of CXCR3 ligands (CXCL9, CXCL10 and CXCL11) to promote T cell infiltration into GBM, thereby enhancing the effects of immunotherapies. Here, CXCL10 is linked to glioblastoma.